June 05, 2013 (Lausanne, Switzerland). Galderma today announced that it has initiated clinical development of a novel muscle relaxant, based on an advanced formulation of botulinum toxin, with the first cohort of patients already treated in the initial clinical study.

“Muscle relaxants are a key medical solution aesthetic physicians can use to create balanced and optimal results for their patients. We aim to strengthen our portfolio with a new and proprietary muscle relaxant in territories where Galderma does not have access to Azzalure/Dysport, such as North America” commented Humberto C. Antunes, President and CEO of Galderma. “We look forward to rapidly advancing this innovative product in countries where we do not currently promote Azzalure or Dysport in aesthetics.”

The first study is expected to be completed in a short period of time, with a second study planned to begin before the end of the year.

According to Medical Insights Inc., a leading independent market research company in aesthetics, the market for muscle relaxants in aesthetics is expected to be $1,211.8 million in 2013 and is projected to exceed $1,588.8 million by 2017 (Published in the Global Aesthetic Market Study, January 2013).
 

For further information, please contact:
Karin Falck
Public and Media Relations Officer
Galderma S.A.
+46 (0) 709749015
 

About Galderma
Galderma is a global company founded in 1981 committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world. The company has 31 wholly-owned affiliates with a worldwide network of distributors and almost 5 000 employees worldwide. Galderma’s extensive product portfolio is available in 70 countries and treats a range of dermatological conditions including: acne, rosacea, onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence.
With approximately 20 percent of revenues invested each year to discover and develop new products and access innovative technologies, the company is one of the world’s leading investors in dermatology R&D. Four state-of-the-art R&D centers and four manufacturing sites are dedicated to providing a wide range of innovative medical solutions which meet the highest standards of safety and efficacy. Strategic brands include Epiduo®, Oracea®, Clobex®, Differin®, Rozex®/MetroGel®, Silkis®/Vectical®, Tri-Luma®, Loceryl®, Cetaphil®, Metvix®, Azzalure®, Restylane® and Emervel®.